Publications by the researcher in collaboration with Jesús Santos González (32)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  3. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

2020

  1. Addition of maraviroc versus placebo to standard antiretroviral therapy for initial treatment of advanced HIV infection: A randomized trial

    Annals of Internal Medicine, Vol. 172, Núm. 5, pp. 297-305

  2. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

  3. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  4. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

2019

  1. Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 151-159

  2. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202

  3. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice

    The Journal of antimicrobial chemotherapy, Vol. 74, Núm. 6, pp. 1693-1700

2018

  1. Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 36, Núm. 5, pp. 268-276

  2. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

  2. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  3. Overall and cause-specific excess mortality in HIV-positive persons compared with the general population Role of HCV coinfection

    Medicine (United States), Vol. 95, Núm. 36

  4. Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy

    HIV Medicine, Vol. 17, Núm. 9, pp. 653-661

2015

  1. Cardiovascular risk factors and lifetime risk estimation in hiv-infected patients under antiretroviral treatment in Spain

    HIV Clinical Trials, Vol. 16, Núm. 2, pp. 57-65